Among 208,155 bariatric surgery patients in a nationwide US cohort (2018–2025), 39,750 who subsequently received incretin-based therapy for at least one year showed clinically meaningful additional weight loss. Tirzepatide (dual GIP/GLP-1 agonist) produced 17.2% total weight loss versus 12.0% with semaglutide — an adjusted difference of 5.16 percentage points (95% CI 4.17–6.16) — in a dose-dependent fashion. Intriguingly, later initiation of therapy (postoperative months 53–79) yielded greater weight loss than earlier initiation (months 12–24), suggesting a potential synergistic window. Pooled incretin therapy showed no statistically significant reduction in major adverse cardiovascular events (HR 0.91, 95% CI 0.80–1.05).
This is the largest real-world dataset examining incretin therapy as a post-bariatric adjunct, and the tirzepatide-versus-semaglutide magnitude gap aligns with the SURMOUNT and SELECT trial hierarchies in the general population — confirming the dual-agonist advantage persists even atop surgical weight loss. The finding that later initiation outperforms earlier use is counterintuitive and warrants mechanistic investigation; it may reflect hormonal adaptation post-surgery or patient selection bias in this retrospective design. The neutral cardiovascular signal is the study's most significant limitation — propensity matching can't fully correct for confounding, and the cohort may be underpowered for MACE detection. This is confirmatory-plus rather than paradigm-shifting, but meaningfully advances clinical guidance for the growing population experiencing post-bariatric weight recurrence.
